TIANDA PHARMA released its interim results, with a loss attributable to shareholders of HKD 33.237 million, an increase of 22.03% year-on-year
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, TIANDA PHARMA released its mid-term results for 2025, reporting revenue of HKD 137 million, a year-on-year decrease of 12.45%; the loss attributable to shareholders of the company was HKD 33.237 million, a year-on-year increase of 22.03%; basic loss per share was HKD 1.55
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments